Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

News in Brief

COVID-19 Challenges Basic Researchers

DOI: 10.1158/2159-8290.CD-NB2020-018 Published May 2020
  • Article
  • Info & Metrics
Loading

As COVID-19 cases have continued to surge, federal agencies such as the Centers for Disease Control and Prevention have called for vigilant social distancing and quarantining to stop the spread. At cancer centers, that has left scientists engaged in basic research facing difficult decisions about which experiments to continue, while securing supplies and creating contingency plans for a complete shutdown.

“We are able to continue to do research, but we don't know how much longer that will happen,” says Ruth Keri, PhD, associate director for basic research at the Case Comprehensive Cancer Center in Cleveland, OH. “We take each day as it comes.”

To limit the number of people in labs, researchers are working in shifts. Case has directed researchers to stop nonessential experiments—something Keri says “is in the eye of the beholder”—and to spend a minimal amount of time on essential experiments. Her lab has begun to protect its work by, for example, freezing organoids developed from patient-derived xenografts and portions of cell lines to safeguard against a shutdown, which may come with just a day or two notice.

The Perlmutter Cancer Center, NYU Langone Health in New York, NY, rapidly transitioned from a lab policy of social distancing to one that only permits “mission-essential” experiments. Now, no new experiments can be started, says Benjamin Neel, MD, PhD, director of NYU Langone. Researchers can continue to maintain long-term experiments but have been directed to pause experiments they'd already started when they reach a stopping point—for example, growing cells and cell lines until they can be frozen.

Animal models, which can be years in the making, are key to cancer research. Case is no longer receiving new mouse shipments but will continue ongoing mouse studies, many of which are investigating tumor growth or response to novel agents. NYU Langone has adopted a similar policy, but “the real concern is long-standing mouse experiments,” Neel says. “We're trying to thread the needle between safety, which is certainly our top priority, and, if possible, trying to limit the loss of mission-critical things,” he says.

Researchers are also concerned about supplies, which could become scarce as the pandemic continues. “We tried to be very prospective about 2 weeks ago and order all the things we thought we would need to continue doing essential experiments,” Keri explains, a list that includes everything from cell culture serum to pipette tips. Neel asked investigators to secure a 2-month supply of CO2 and extra liquid nitrogen, but not to order highly perishable supplies in case of a shutdown.

Displaced from the lab, many researchers are catching up on other work. “I submitted a grant this morning, I worked on a paper yesterday—I'm doing the things during the daytime that I typically do from 10 pm to 2 am,” says Roy Jensen, MD, director of The University of Kansas Cancer Center in Kansas City, who has encouraged researchers to put experiments on hold and work from home. Eventually, however, “there will come a time when you're caught up on those things, and to make additional progress, you've got to get back in the lab.”

As for the long-term impact on basic cancer research, the duration of the pandemic is key. “Is it going to be for 6 weeks or 6 months?” Jensen wonders.

“Experiments can be started over again,” Neel adds, “people can't.” –Catherine Caruso

  • ©2020 American Association for Cancer Research.
PreviousNext
Back to top
Cancer Discovery: 10 (5)
May 2020
Volume 10, Issue 5
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
COVID-19 Challenges Basic Researchers
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
COVID-19 Challenges Basic Researchers
Cancer Discov May 1 2020 (10) (5) OF3; DOI: 10.1158/2159-8290.CD-NB2020-018

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
COVID-19 Challenges Basic Researchers
Cancer Discov May 1 2020 (10) (5) OF3; DOI: 10.1158/2159-8290.CD-NB2020-018
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • ADC Successfully Targets Urothelial Cancer
  • Break Through Cancer Launches with $250M Pledge
  • By The Numbers: Novel Drugs Approved by the FDA, 2011-2020
Show more News in Brief
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement